Beta-glucan on Fecal Microflora in Polypectomized Patients

Harokopio University69 enrolled

Overview

The aim of this study is to determine the effect of the potential prebiotic beta-glucan on the intestinal microflora, the bacterial enzyme activity (beta-glucuronidase and beta-glucosidase) in the feces, the fecal pH and the concentration of fecal short-chain fatty acid in polypectomized patients. Also the in vitro anti-cyto- and anti-genotoxicity of fecal water will be examined on human cell culture (HT29). During the trial, patient's clinical symptoms (intestinal habits), physical activity, well-being and food intake will be recorded.

Prebiotics, such as short- and long-chain fructo-oligosaccharides are fermented by the microflora colonizing the gastrointestinal tract, and they selectively stimulate the growth or the activity of one or limited number of bacteria within the intestine. Beta-glucans are polysaccharides occurring in the bran of cereal grains, the cell wall of Saccharomyces cerevisiae and bacteria, certain types of fungi, seaweed and many kinds of mushrooms. The aim of this study is to determine the effect of the potential prebiotic beta-glucan on the intestinal microflora, the bacterial enzyme activity (beta-glucuronidase and beta-glucosidase) in the faeces, the faecal pH, and the concentration of faecal short-chain fatty acid in polypectomized patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

Conditions

Polypectomized Patients

Interventions

wheat bread with beta-glucanDIETARY_SUPPLEMENT

3 g beta-glucan in approximately 200 g of wheat bread per day for 3 months

wheat bread without beta-glucanDIETARY_SUPPLEMENT

Approximately 200 g of wheat bread (without beta-glucan supplementation) per day for 3 months

Eligibility

Sex: ALLMin age: 20 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * The subjects must have biopsy and histologically confirmed adenomatous polyps ≥ 1cm in size or ≥ 3 in number with moderate or severe dysplasia Exclusion Criteria: * Subjects ≥ 75 years of age * Subjects who are pregnant or desire to become pregnant during the study period * Subjects who are considered to be poor clinic attendees * Subjects who have been on antibiotics within the previous month or are likely to require antibiotics during the trial * Subjects who consume prebiotics or probiotics within the previous month or are likely to require antibiotics during the trial * Subjects with colon cancer * Subjects with additional gastrointestinal disorders (e.g., Crohn's disease or ulcerative colitis) * Subjects with malignancy or any end-stage organ disease

Locations (1)

Harokopio University

Athens, Attica, Greece

Outcomes

Primary Outcomes

To measure the effect of beta-glucan on fecal microflora (number of bacteria, bacterial enzyme activity, SCFA, pH).

Time frame: four months

To observe the effect of beta-glucan on intestinal symptoms and well-being.

Time frame: four months

Secondary Outcomes

To study the fecal water cyto- and/or genotoxicity on HT-29 cell line.

Time frame: one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.